Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. Fuzeon, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. Trimeris is developing Fuzeon and future generations of peptide fusion inhibitors in collaboration with F. Hoffmann-La Roche Ltd. ( www.trimeris.com )
Trimeris , Inc.
3500 Paramount Parkway
Morrisville, North Carolina 27560
USA
Tel: (919) 419-6050
Fax: (919) 419-1816